Navigation Links
Misonix, Inc. Announces First Quarter Fiscal Year 2014 Financial Results

FARMINGDALE, N.Y., Nov. 7, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today announced financial results for the first quarter of fiscal year 2014 ended September 30, 2013.

Highlights for the quarter included:

  • Net sales for the quarter were $3.1 million compared to $4.6 million as the Company continues to transition to a unit consignment strategy to drive recurring revenue.
  • BoneScalpel™ units sold or placed totaled 36 world-wide in first quarter fiscal 2014.
  • BoneScalpel units placed or sold in the United States during the quarter totaled 15 compared to 7 in the first quarter of fiscal 2013; excluding sales to Aesculap.
  • BoneScalpel disposable sales in Latin America increased 110% in Q1 fiscal 2014.
  • U.S. BoneScalpel disposable revenue increased 74% driven by a 65% increase in disposable utilization; excluding Aesculap.
  • Across all businesses, recurring revenue for all products world-wide, for the quarter accounted for 53% of total sales during the quarter; compared to 40% in fiscal first quarter 2013.
  • Arrangements to roll-out BoneScalpel and SonaStar® in China are progressing after receiving regulatory approval.
  • First Quarter Fiscal 2014 Financial ResultsRevenue for the three months ended September 30, 2013 was $3.1 million, a 33% decrease when compared to $4.6 million for the same period in fiscal 2013.  Part of the decrease was attributable to the approximate $363,000 lower revenue from Aesculap and lower stocking sales to international markets as compared to the same quarter in fiscal 2013.

    BoneScalpel revenue was $1.3 million, SonaStar revenue was $1.1 million and SonicOne® revenue was $469,000 for the first quarter 2014. 

    There were 36 BoneScalpel units sold or placed during the first quarter fiscal 2014 compared to 57 BoneScalpel units sold or placed during the first quarter of fiscal 2013.  BoneScalpel domestic disposable sales increased 74% during the first quarter fiscal 2014 compared to the same period in fiscal 2013, excluding Aesculap.

    The Company reported a net loss of $884,002, or ($.12) diluted loss per share, compared to net income of $44,834, or $0.01 earnings per share, in fiscal 2013. 

    Michael A. McManus, Jr., President and CEO, stated, "This was another quarter for progress for your Company.  You will remember our strategy of consigning units in conjunction with purchases of our disposable blade.  The result of this formula shows continued high margins and an increase of BoneScalpel units in the U.S.  BoneScalpel revenue from disposables increased 74% in the U.S., excluding Aesculap, resulting from an increase of 65% in disposable units from the first quarter of fiscal 2013.  Total recurring revenue from disposables increased to 53% of total sales for the quarter.  These results are all indicators of growth and surgeons continued acceptance and use of our unique technology.  The acceptance of the significant benefits to doctor, patient and hospital are consistently increasing.  We expect to see growth across all products and in all markets over the coming quarter." 

    "We are excited about the reception we are receiving at prominent trade shows and professional conferences.  We are experiencing considerable traffic from both surgeons and potential new distributors.  Testimony from prominent surgeons at these meetings is particularly encouraging and has been reported in recent press releases."

    Mr. McManus concluded, "We are executing on our strategy to deliver more predictable revenue streams from high margin sales.  We are seeing indications for expected growth across the upcoming quarters."Conference Call:The Company has scheduled a conference call today, Thursday, November 7, 2013, at 4:30 pm ET to review the results. Interested parties can access the conference call by dialing (877) 317-6789 or (412) 317-6789 or can listen via a live Internet webcast, which is available in the Investor Relations section of the Company's website at

    A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10036674. A webcast replay will be available in the Investor Relations section of the Company's website at for 30 days. 

    About MisonixMisonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at

    Safe Harbor StatementWith the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.Investor Relations Contacts: Misonix Contact:Lytham Partners, LLCRichard Zaremba  Robert Blum, Joe Dorame, Joe 

    Financial Tables to FollowMISONIX, INC. And Subsidiaries Consolidated Balance SheetsSeptember 30, 2013June 30, 2013(Unaudited)(derived fromaudited financialstatements)AssetsCurrent Assets:  Cash and cash equivalents$4,653,513$5,806,437  Accounts receivable, less allowance for doubtful accounts of $229,641 and $214,641, respectively2,799,3362,974,641  Inventories, net4,157,1934,034,477  Prepaid expenses and other current assets294,079387,371Total current assets11,904,12113,202,926Property, plant and equipment, net1,185,0381,326,586Goodwill1,701,0941,701,094Intangible and other assets1,073,9961,129,321Total assets$15,864,249$17,359,927Liabilities and stockholders' equityCurrent liabilities:  Accounts payable$1,601,445$2,208,999  Accrued expenses and other current liabilities1,024,8441,276,963Total current liabilities2,626,2893,485,962Deferred income61,88172,934Deferred lease liability22,01223,811Total liabilities2,710,1823,582,707Commitments and contingenciesStockholders' equity:  Capital stock, $0.01 par value - shares authorized 20,000,000, 7,267,096 and 7,233,884 shares issued and 7,189,536 and 7,156,324 shares outstanding, respectively72,67172,339  Additional paid-in capital27,250,07626,989,559  Accumulated deficit(13,757,687)(12,873,685)  Treasury stock, at cost, 77,560 shares(410,993)(410,993)Total stockholders' equity13,154,06713,777,220Total liabilities and stockholders' equity$15,864,249$17,359,927MISONIX, INC. And SubsidiariesCondensed Consolidated Statements of OperationsUnauditedThree Months EndedSeptember 302013

    2012Net sales


    $4,570,525Cost of goods sold


    1,843,899Gross profit


    2,726,626Selling expenses


    1,458,564General and administrative expenses


    1,042,332Research and development expenses


    397,131Total operating expenses


    2,898,027Loss from operations


    (171,401)Total other income


    211,417(Loss) income from continuing operations before  income taxes


    40,016Income tax expense


    1,500Net (loss) income from continuing operations


    38,516Net income from discontinued operations, net of tax


    6,318Net (loss) income 


    $44,834Net (loss) income per share from continuing operations-Basic


    $0.01Net income per share from discontinued operations-Basic


    0.00Net (loss) income per share-Basic


    $0.01Net (loss) income per share from continuing operations-Diluted


    $0.01Net income per share from discontinued operations-Diluted


    0.00Net (loss) income per share-Diluted


    $0.01Weighted average common shares-basic


    7,005,360Weighted average common shares-diluted



    SOURCE Misonix, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Misonix, Inc. Announces the Grant of Patent by the United States Patent and Trademark Office
    2. Misonix, Inc. Announces Fourth Quarter and Fiscal Year 2013 Financial Results
    3. Misonix, Inc. To Report Financial Results For The First Quarter Of Fiscal Year 2014 On Thursday, November 7, 2013
    4. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
    5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
    6. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
    7. Misonix Announces New Distribution Agreement For Panama
    8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
    9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
    10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
    11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
    Post Your Comments:
    (Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ... Aspen Surgical facility in Las Piedras, Puerto ... scalpels and blades. ... that the facility sustained minor structural damage, temporary loss ... Maria. Repairs have been completed, manufacturing operations have resumed, ...
    (Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
    (Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
    Breaking Medicine Technology:
    (Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
    (Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
    (Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
    (Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
    Breaking Medicine News(10 mins):